Maze Therapeutics reports success in Phase 2 kidney disease trial as cash runway extends into 2028
Maze Therapeutics (NASDAQ:MAZE), a clinical-stage biopharmaceutical company applying genetic insights to the development of precision medicines, reported its fourth-quarter and full-year 2025 financial results on Wednesday, March 25, 2026.
-1-640x359.webp&w=3840&q=75)









